NCT06329570View on ClinicalTrials.gov

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Glioblastoma MultiformeGlioblastomaGliomaBrain TumorNeoplasmsNeoplasms, Nerve Tissue
Interventions
DEVICE

NaviFUS System

Open the BBB using focused ultrasound and microbubble

DRUG

Lumason

Open the BBB using focused ultrasound and microbubble

DRUG

Bevacizumab

An anti-angiogenic agent to block tumor growth

Trial Locations (1)

22903

University of Virginia, Charlottesville

Sponsors
All Listed Sponsors
collaborator

NaviFUS US LLC

UNKNOWN

lead

NaviFUS Corporation

INDUSTRY

NCT06329570 - Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) | Biotech Hunter | Biotech Hunter